StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.45−0.16 (-2.10%)

Close on Nov 16, 2026Market cap $1.90BP/E –Yield –

BioCryst Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

BioCryst Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -37.4%. For fiscal 2025 it was 30.2%, against -19.7% the year before. The highest annual figure on record is 30.2% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202530.2%+49.9
FY2024Dec 31, 2024-19.7%+48.6
FY2023Dec 31, 2023-68.4%+22.9
FY2022Dec 31, 2022-91.2%+25.9
FY2021Dec 31, 2021-117.1%+909.2
FY2020Dec 31, 2020-1026.4%−803.4
FY2019Dec 31, 2019-223.0%+267.3
FY2018Dec 31, 2018-490.3%−229.1
FY2017Dec 31, 2017-261.2%−51.9
FY2016Dec 31, 2016-209.3%−120.1
FY2015Dec 31, 2015-89.1%+242.9
FY2014Dec 31, 2014-332.1%−158.4
FY2013Dec 31, 2013-173.7%−25.1
FY2012Dec 31, 2012-148.6%+141.3
FY2011Dec 31, 2011-289.9%−235.6
FY2010Dec 31, 2010-54.3%−36.2
FY2009Dec 31, 2009-18.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202621.0%+12.9
Q2 FY2026Jun 30, 202635.9%+32.8
Q1 FY2026Mar 31, 2026-461.5%−461.5
Q4 FY2025Dec 31, 202560.5%+80.8
Q3 FY2025Sep 30, 20258.1%+20.1
Q2 FY2025Jun 30, 20253.1%+14.7
Q1 FY2025Mar 31, 20250.0%+38.2
Q4 FY2024Dec 31, 2024-20.4%+45.7
Q3 FY2024Sep 30, 2024-12.0%+29.7
Q2 FY2024Jun 30, 2024-11.6%+79.7
Q1 FY2024Mar 31, 2024-38.1%+39.4
Q4 FY2023Dec 31, 2023-66.1%+23.8
Q3 FY2023Sep 30, 2023-41.7%+14.4
Q2 FY2023Jun 30, 2023-91.3%−1.5
Q1 FY2023Mar 31, 2023-77.5%+71.1
Q4 FY2022Dec 31, 2022-89.9%−52.2
Q3 FY2022Sep 30, 2022-56.1%+87.4
Q2 FY2022Jun 30, 2022-89.8%−3.4
Q1 FY2022Mar 31, 2022-148.6%+188.7
Q4 FY2021Dec 31, 2021-37.7%+1468.6
Q3 FY2021Sep 30, 2021-143.4%+612.3
Q2 FY2021Jun 30, 2021-86.5%+1258.3
Q1 FY2021Mar 31, 2021-337.3%+442.3
Q4 FY2020Dec 31, 2020-1506.3%−1499.7
Q3 FY2020Sep 30, 2020-755.7%+1362.1
Q2 FY2020Jun 30, 2020-1344.7%+1254.0
Q1 FY2020Mar 31, 2020-779.6%−252.1
Q4 FY2019Dec 31, 2019-6.6%+998.6
Q3 FY2019Sep 30, 2019-2117.9%−82.3
Q2 FY2019Jun 30, 2019-2598.7%−2451.0
Q1 FY2019Mar 31, 2019-527.5%+120.8
Q4 FY2018Dec 31, 2018-1005.2%−502.8
Q3 FY2018Sep 30, 2018-2035.6%−1862.8
Q2 FY2018Jun 30, 2018-147.6%+397.2
Q1 FY2018Mar 31, 2018-648.3%−497.6
Q4 FY2017Dec 31, 2017-502.4%−452.3
Q3 FY2017Sep 30, 2017-172.8%–
Q2 FY2017Jun 30, 2017-544.9%–
Q1 FY2017Mar 31, 2017-150.7%–
Q4 FY2016Dec 31, 2016-50.1%–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?